Chiara Tarantelli
Bellinzona, TI, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates.
Journal: Leukemia & lymphoma
Published: September 07, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.
Journal: Cancer medicine
Published: October 11, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: Blood
Published: May 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: Blood
Published: May 14, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.
Journal: Haematologica
Published: December 12, 2024
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma.
Journal: Hematological oncology
Published: April 23, 2024
Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma.
Journal: Animals : an open access journal from MDPI
Published: April 18, 2024
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype.
Journal: Hematological oncology
Published: April 18, 2024
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Journal: bioRxiv : the preprint server for biology
Published: November 28, 2023
Last Updated: 09/26/2026